While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant that title regardless of what's transpired in 2025. Among them are CRISPR ...

Learn more about whether Elastic N.V. or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, which ...

How GLP-1 drugs, regulatory concerns, and more factors are shaping the sector. Plus, 3 undervalued healthcare stocks.

In the last year, some drugmakers have pulled back from the sector, including Pfizer, which recently stopped selling its gene ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

The diabetes market is booming, with continuous glucose monitoring (CGM) and GLP-1 drugs leading the charge in innovation and ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

Both stocks should deliver excellent returns to investors patient enough to hold through volatility. Equity markets started ...

The funds will facilitate the clinical progression of ABO-101, the company’s lead therapeutic candidate targeting PH1.

Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed ...

Vertex Pharmaceuticals is ranked among the best biotech stocks to buy, with 13 billionaires backing the company. Despite ...

Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investorsFinancing extends Arbor’s cash ...